Latest Content by PharmaCompass
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
About
Industry Trade Show
Not Confirmed
17-20 March, 2025
World ADC LondonWorld ADC London
Industry Trade Show
Not Confirmed
03-06 March, 2025
Industry Trade Show
Not Confirmed
04-06 March, 2025
CONTACT DETAILS
Digital content 
CORPORATE CONTENT #SupplierSpotlight
NEWS #PharmaBuzz
08 May 2024
// PRESS RELEASE
02 May 2024
// PRESS RELEASE
09 Apr 2024
// PRESS RELEASE
08 Apr 2024
// PRESS RELEASE
19 Mar 2024
// PRESS RELEASE
29 Feb 2024
// PRESS RELEASE
Drugs in Development
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tiefenbacher Pharmaceuticals Prepares Launch of the Anticoagulant Rivaroxaban
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
April 09, 2024
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Product Name : Aubagio-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2023
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.
Product Name : Bilastine Tiefenbacher
Product Type : Small molecule
Upfront Cash : Not Applicable
March 14, 2023
Lead Product(s) : Apremilast
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.
Product Name : Otezla-Generic
Product Type : HPAPI
Upfront Cash : Inapplicable
December 01, 2022
Lead Product(s) : Abiraterone Acetate,Prednisolone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2022
Lead Product(s) : Apixaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Product Name : Apixaban Tiefenbacher
Product Type : HPAPI
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Vildagliptin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.
Product Name : Vildagliptin-Metformin-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
September 08, 2022
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
July 15, 2022
Lead Product(s) : Teriflunomide
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.
Product Name : Teriflunomide-Generic
Product Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
Dosage Form : Tablet
Dosage Strength : 250MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
Dosage Form : Tablet
Dosage Strength : 500MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
Regulatory Info : Status- Under Registra...
Registration Country : Germany
Dosage Form : Film Coated Tablet
Dosage Strength : 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Status- Under Registra...
Registration Country : Germany
Regulatory Info : Status- Under Registra...
Registration Country : Germany
Dosage Form : Film Coated Tablet
Dosage Strength : 10MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Status- Under Registra...
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Film Coated Tablet
Dosage Strength : 1MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Tablet
Dosage Strength : 10MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Tablet
Dosage Strength : 15MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
Dosage Form : Tablet
Dosage Strength : 2.5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
Dosage Form : Tablet
Dosage Strength : 5MG
Packaging :
Brand Name :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q...
Registration Country : Germany
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Regulatory Info : EU Dossier Readiness-Q1 2019
Registration Country : Germany
Dosage Form : Tablet
Brand Name :
Dosage Strength : 250MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q1 2019
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q1 2019
Registration Country : Germany
Dosage Form : Tablet
Brand Name :
Dosage Strength : 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q1 2019
Registration Country : Germany
Regulatory Info : Status- Under Registration
Registration Country : Germany
Dosage Form : Film Coated Tablet
Brand Name :
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Status- Under Registration
Registration Country : Germany
Regulatory Info : Status- Under Registration
Registration Country : Germany
Dosage Form : Film Coated Tablet
Brand Name :
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Status- Under Registration
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Film Coated Tablet
Brand Name :
Dosage Strength : 1MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Tablet
Brand Name :
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Tablet
Brand Name :
Dosage Strength : 10MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Dosage Form : Tablet
Brand Name :
Dosage Strength : 15MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q4 2018
Registration Country : Germany
Dosage Form : Tablet
Brand Name :
Dosage Strength : 2.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q4 2018
Registration Country : Germany
Regulatory Info : EU Dossier Readiness-Q4 2018
Registration Country : Germany
Dosage Form : Tablet
Brand Name :
Dosage Strength : 5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : EU Dossier Readiness-Q4 2018
Registration Country : Germany
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Alfred E Tiefenbacher GmbH
We are the TIEFENBACHER GROUP, Health Pioneers since 1963.
